Generic drug impurities draft guidance
Executive Summary
FDA releases draft guidance entitled "ANDAs: Impurities in Drug Substances." The document, published in the Federal Register Jan. 31, is the first revision of the original 1999 guidance. The draft guidance suggests companies use stability studies, chemical development studies and routine batch analysis to test for impurities, which can be qualified in four ways...
You may also be interested in...
ANDA Impurity Product Specifications Updated In FDA Draft Guidance
A revised FDA draft guidance updates recommendations on the listing and qualification of degradation products in ANDAs
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.